GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Connect Biopharma Holdings Ltd (NAS:CNTB) » Definitions » EV-to-Revenue

CNTB (Connect Biopharma Holdings) EV-to-Revenue : -1.59 (As of May. 28, 2025)


View and export this data going back to 2021. Start your Free Trial

What is Connect Biopharma Holdings EV-to-Revenue?

EV-to-Revenue is calculated as enterprise value divided by its revenue. As of today, Connect Biopharma Holdings's enterprise value is $-41.32 Mil. Connect Biopharma Holdings's Revenue for the trailing twelve months (TTM) ended in Dec. 2024 was $26.03 Mil. Therefore, Connect Biopharma Holdings's EV-to-Revenue for today is -1.59.

The historical rank and industry rank for Connect Biopharma Holdings's EV-to-Revenue or its related term are showing as below:

CNTB' s EV-to-Revenue Range Over the Past 10 Years
Min: -2.27   Med: -1.82   Max: -1.1
Current: -1.59

During the past 6 years, the highest EV-to-Revenue of Connect Biopharma Holdings was -1.10. The lowest was -2.27. And the median was -1.82.

CNTB's EV-to-Revenue is ranked better than
94.09% of 998 companies
in the Biotechnology industry
Industry Median: 7.38 vs CNTB: -1.59

The reason Enterprise Value is used is because Enterprise Value is more real in reflecting how much an investor pays when buying a company. For detais, go to Enterprise Value.

EV-to-Revenue is a similar ratio to PS Ratio, except here Enterprise Value instead of Market Cap is used in the calculation.

As of today (2025-05-28), Connect Biopharma Holdings's stock price is $0.7799. Connect Biopharma Holdings's Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2024 was $0.47. Therefore, Connect Biopharma Holdings's PS Ratio for today is 1.66.


Connect Biopharma Holdings EV-to-Revenue Historical Data

The historical data trend for Connect Biopharma Holdings's EV-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Connect Biopharma Holdings EV-to-Revenue Chart

Connect Biopharma Holdings Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
EV-to-Revenue
Get a 7-Day Free Trial - - - - -0.66

Connect Biopharma Holdings Semi-Annual Data
Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24
EV-to-Revenue Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only - - - - -0.66

Competitive Comparison of Connect Biopharma Holdings's EV-to-Revenue

For the Biotechnology subindustry, Connect Biopharma Holdings's EV-to-Revenue, along with its competitors' market caps and EV-to-Revenue data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Connect Biopharma Holdings's EV-to-Revenue Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Connect Biopharma Holdings's EV-to-Revenue distribution charts can be found below:

* The bar in red indicates where Connect Biopharma Holdings's EV-to-Revenue falls into.


;
;

Connect Biopharma Holdings EV-to-Revenue Calculation

EV-to-Revenue is a similar ratio to PS Ratio, except here Enterprise Value instead of Market Cap is used in the calculation.

Connect Biopharma Holdings's EV-to-Revenue for today is calculated as:

EV-to-Revenue=Enterprise Value (Today)/Revenue (TTM)
=-41.318/26.033
=-1.59

Connect Biopharma Holdings's current Enterprise Value is $-41.32 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Connect Biopharma Holdings's Revenue for the trailing twelve months (TTM) ended in Dec. 2024 was $26.03 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Connect Biopharma Holdings  (NAS:CNTB) EV-to-Revenue Explanation

The reason Enterprise Value is used is because Enterprise Value is more real in reflecting how much an investor pays when buying a company. For detais, go to Enterprise Value.

Connect Biopharma Holdings's PS Ratiofor today is calculated as:

PS Ratio=Share Price (Today)/Revenue per Share (TTM)
=0.7799/0.469
=1.66

Connect Biopharma Holdings's share price for today is $0.7799.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. {COMPANY->company}'s Revenue per Sharefor the trailing twelve months (TTM) ended in Dec. 2024 was $0.47.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Connect Biopharma Holdings EV-to-Revenue Related Terms

Thank you for viewing the detailed overview of Connect Biopharma Holdings's EV-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.


Connect Biopharma Holdings Business Description

Traded in Other Exchanges
N/A
Address
12265 El Camino Real, Suite 350, San Diego, CA, USA, 92130
Connect Biopharma Holdings Ltd is a clinical-stage company focused on the discovery and development of next-generation immune modulators for the treatment of serious autoimmune diseases and inflammation. It has leveraged its expertise in the biology of T cell modulation to build a portfolio of drug candidates consisting of small molecules and antibodies targeting critical pathways of inflammation. Its pipeline includes CBP-201, CBP-307 and CBP-174.